Yilmaz Mesut, Yasar Canan, Aydin Selda, Derin Okan, Ceylan Bahadir, Mert Ali
Department of Infectious Diseases and Clinical Microbiology, Medipol Mega Hospital Complex, Istanbul Medipol University, TEM Avrupa Otoyolu Goztepe Cikisi No: 1, Bagcilar, 34214, Istanbul, Turkey.
Drug Saf Case Rep. 2018 Feb 9;5(1):9. doi: 10.1007/s40800-018-0074-3.
We present a 35-year-old female patient who was started on rifampicin (900 mg orally once daily) and trimethoprim/sulfamethoxazole (TMP/SMX) (160/800 mg orally twice daily) after being diagnosed with brucellosis. Following defervescence and improvement in her general condition, fever recurred on the 12th day of treatment. A re-challenge drug test lead to causality assessment and treatment was switched to a combination of streptomycin (1 g intramuscularly) for 10 days and TMP/SMX (160/800 mg orally twice daily) for 4 weeks. Our patient is doing well after 12 months of follow-up.
我们报告一位35岁的女性患者，她在被诊断为布鲁氏菌病后开始服用利福平（每日口服一次，900毫克）和甲氧苄啶/磺胺甲恶唑（TMP/SMX）（每日口服两次，160/800毫克）。在体温下降且一般状况改善后，治疗第12天发热复发。重新进行的激发药物试验用于因果关系评估，治疗改为联用链霉素（每日1克，肌肉注射），共10天，以及TMP/SMX（每日口服两次，160/800毫克），共4周。经过12个月的随访，我们的患者情况良好。
